PreludeDx™ to Present DCISionRT® and Novel Residual Risk Subtype Study Results During Scientific Oral Session at ASBrS 2022 Annual Meeting
/PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that...
Source: prnewswire.com